Introduction
Primary B-cell immunodeficiencies are conditions characterized by the decreased generation of antibodies due to either B-cell intrinsic molecular abnormalities or a breakdown in the connection between B-cells and T-cells. According to the location of the B-cell development defect or the level of functional impairment, patients often have recurring infections and might present differently and experience different consequences. The B-cell-specific immunological abnormalities are characterized by the presence or lack of peripheral B cells, immunoglobulin isotypes, and signs of antibody dysfunction.
Immunoglobulins, which comprise around 20 % of serum proteins, include all the different types of antibodies humans require to be protected against most illnesses. Creating functional antibodies involves several phases, including the ongoing reconfiguration of the B-cell antigen receptor (BCR) genes and the potential 90 % eradication of polyreactive and autoreactive B-cells during this process. The broad umbrella term B-cell disease covers several diseases and immunodeficiency states.
What Are the Types of Primary B-cell Immunodeficiencies?
1. Agammaglobulinemia: Extremely low levels of all serum immunoglobulin isotypes and abnormally low or absent B-cells.
2. X-linked Agammaglobulinemia (XLA):
-
Agammaglobulinemia is characterized by a dramatic decrease in all blood immunoglobulin levels and the lack of circulating B-cells.
-
Clinically speaking, this defect is rare. The condition has both X-linked and autosomal recessive variants, according to descriptions.
-
The X-linked agammaglobulinemia (XLA), a condition that affects the development of B cells, was originally identified in 1952 by Ogden Bruton, who also reported the case of an eight-year-old child who experienced recurrent bacterial sepsis and had no globulin fraction on blood protein electrophoresis.
-
An X-linked inheritance pattern was discovered as more cases were identified. The absence of circulating B-cells is the defining feature of XLA.
-
The presence of pro-B-cell and pre-B-cells in the bone marrow suggests that hematopoietic stem cells enter the B-cell lineage, but these cells cannot mature effectively.
3. Autosomal Agammaglobulinemias:
-
Anomaly of the pre-BCR complex or downstream signaling pathways is the primary cause of agammaglobulinemia with an autosomal recessive inheritance pattern. A functioning pre-BCR complex must be expressed on the cell surface for the pro-B-cell to pre-B-cell transition, successive immunoglobulin gene rearrangements, and normal B-cell development to occur.
-
Autosomal types of agammaglobulinemia are consequently caused by abnormalities in the BCR structure itself, including the heavy chain, surrogate light chains (VpreB and 5), the Ig (CD79) and Ig genes (CD79B), which constitute the heterodimeric transmembrane signal transduction components. IGHM (located on chromosome 14q32.33) is the second most often mutant gene in agammaglobulinemia patients after BTK, the gene encoding for the heavy chain, but only accounts for roughly 5% of agammaglobulinemia patients.
-
The total lack of B-cells in the peripheral circulation is linked to every documented serious chain mutation. Although point mutations have been observed less often, massive deletions encompassing the IGHM gene (OMIM: 147020) account for up to 60 % of alterations. Patients with heavy chain abnormalities tend to have a more severe phenotype and are detected earlier than patients with BTK mutations, despite the significant clinical overlap.
4. Common Variable Immune Deficiency (CVID) Phenotype: Severe decline in serum immunoglobulins with normal or low B-cells.
5. Common Variable Immune Deficiency (CVID):
-
B-cells travel from the bone marrow to the spleen and peripheral lymphoid organs during early B-cell development and the successful creation of cells with a functioning BCR, where different maturational processes result in the formation of plasma cells.
-
Hypogammaglobulinemia in varied degrees arises from skipping any of these processes. Clinically speaking, individuals are often diagnosed with common variable immune deficiency (CVID).
-
B-cells either do not fully activate, proliferate correctly, or terminally differentiate into plasma cells, and memory B-cells, which represent the multiple developmental roadblocks that cause CVID, are one of the key problems with the condition.
-
Although there are no known genetic defects in the vast majority of CVID patients, the genetic cause has been found in 10 % of all cases. The key types will be covered here.
-
This has revealed hints as to the phases of B-cell development that are faulty. The prevalence of CVID, one of the most prevalent symptomatic primary immunodeficiencies, is believed to range between 1: 25,000 and 1: 50,000. Males and females are equally afflicted; most patients are diagnosed between 20 and 45.
-
This diverse group of PIDs, initially identified in 1954, is defined by lower levels of serum immunoglobulin IgG combined with decreased levels of serum IgA and IgM and faulty synthesis of particular antibodies.
6. Hyper IgM Syndrome:
-
Severe serum IgG and IgA reduction with normal or elevated IgM and normal B-cell counts are known as hyper IgM syndrome. Class-switch recombination (CSR) happens in germinal centers after T-cell-dependent B-cell activation.
-
To undergo CSR and somatic hypermutation (SHM), cognate T follicular helper cells assist activated follicular B-cells. Ultimately, CSR and SHM lead to the generation of high-affinity antibodies and the differentiation of B-cells into plasma cells and long-lived memory B-cells. Rare primary immunodeficiencies known as "hyper-IgM syndromes (HIGM)" or immunoglobulin class switch recombination defects are characterized by the inadequate synthesis of switched immunoglobulin isotypes and normal or high IgM levels.
-
Some of the CSR deficits are mostly intrinsic B-cell abnormalities. Mutations bring them on in the enzymes activation-induced cytidine deaminase (AID) and uracil-DNA glycosylase (UNG). The interaction between activated CD4+ T-cells expressing CD40L and cell types expressing CD40, such as B-cells, dendritic cells, monocytes or macrophages, platelets, and activated endothelial or epithelial cells, is hindered in contrast to CD40 ligand (CD40L) and CD40 deficits.
7. Selective IgA Deficiency (SIGAD):
The most prevalent primary antibody deficit, selective IgA deficiency, has a global prevalence that varies depending on ethnic origin (1:143 to 1:18,500). It is characterized as a serum IgA level of less than 7 mg/dl and normal serum IgG and IgM levels in a patient older than four. It affects both men and women equally. Secondary causes brought on by pharmaceuticals such as anticonvulsants (phenytoin, carbamazepine, valproic acid), disease-modifying anti-rheumatic drugs (sulfasalazine, hydroxychloroquine), nonsteroidal anti-inflammatory drugs, and others must be separated from primary IgA deficiency.
How Is Primary B-Cell Disease Diagnosed?
-
Clinical history is first used to diagnose a primary B-cell deficiency, followed by confirmation laboratory tests. A thorough family and illness history, the age at which symptoms first appeared, the frequency and length of treatments, and, if known, any organisms that would point to a primary B-cell deficiency or a combination of B- and T-cell immunological malfunction are also included.
-
Complete blood counts, full lymphocyte panels for T-cell, B-cell, and NK-cell subsets, quantitative serum immunoglobulin levels (IgM, IgG, IgA, and IgE where indicated), and evaluation of particular antibody responses to both protein and polysaccharide antigens are among the laboratory evaluations that are included.
-
The patient's age should be considered when interpreting immunoglobulin levels.
-
IgG subclasses can be helpful, but often they are only read in light of how well a vaccination has worked. B- and T-cell immunophenotyping is a helpful adjuvant for subcategorization, prognostication, and therapy.
-
Molecular diagnosis; a known gene abnormalities may be commercially sequenced, including panels for primary antibody deficiencies.
What Is the Standard Line of Treatment in Primary B-Cell Disease?
-
Replacement Treatment: The key to treating individuals with verified loss of functional IgG is adequate antibody replacement treatment, with intravenous or subcutaneous immune globulin formulations serving as the mainstay of the patient's care.
-
Microbial Therapy: Utilized in rare circumstances, persistent antibiotic prophylaxis is used. The multidisciplinary approach to management must continue to include surveillance and monitoring for non-infectious complications linked to more severe B-cell defects, such as chronic lung disease, gastrointestinal disease, autoimmunity, and malignancy. Treating these complications early is crucial.
-
Target Therapeutic Approaches: Rapamycin is utilized for targeted therapy to block the physiologically important downstream PI3K effector mechanistic target of the Rapamycin (mTOR) pathway. In addition, there is growing evidence that APDS-causing p110delta mutations can benefit from using a specific PI3Kdelta inhibitor (Leniolisib or CDZ173).
-
CTLA4-Fusion Protein Replacement (Abatacept and Belatacept): To treat patients with CTLA4 and LRBA deficiencies and reverse life-threatening infiltrative and autoimmune illnesses. More clinical research is required to ascertain the efficacy and safety of these targeted medicines.
- Hematopoietic Stem Cell Therapy (HSCT): A widening range of immunodeficiencies have been successfully treated with hematopoietic stem cell therapy (HSCT), which should be pursued as combination immunodeficiencies and taken into consideration as a treatment option for patients with genetic mutations that impede immune response. However, immunoglobulin replacement is the majority of treatment for primary B-cell abnormalities. Still, the only curative option for CD40L deficiency is HSCT, with one of the largest cohorts having a 58 % cure rate.
Conclusion
Murine models have shown the most fundamental concepts of B-cell biology, but the knowledge of human B-cell immunity is mainly based on primary immunodeficiencies. For example, the elucidation of the tyrosine kinase BTK, essential for the maturation of mature B-cells, was made possible by X-linked agammaglobulinLikewise, autosomalosomal agammaglobulinemia, caused by defects in every BCR component, shows how crucial BCR signals are for the upkeep of mature B-cell populations. Similarly, the integrity of the BAFF receptor is crucial.
